An Open-label, Multicenter, Phase 1b Study of JNJ-63723283, a PD-1 Inhibitor, Administered in Combination With Apalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer
Phase of Trial: Phase I
Latest Information Update: 11 Nov 2019
Price : $35 *
At a glance
- Drugs Apalutamide (Primary) ; Cetrelimab (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Janssen Research & Development
- 26 Jul 2019 Planned End Date changed from 17 Oct 2021 to 8 Jun 2022.
- 23 May 2019 Planned End Date changed from 29 Jan 2021 to 17 Oct 2021.
- 02 Apr 2019 Planned number of patients changed from 60 to 98.